Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on June 25, 2009
Japanese Journal of Clinical Oncology 2009 39(9):616-620; doi:10.1093/jjco/hyp070
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/9/616    most recent
hyp070v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ichikawa, Y.
Right arrow Articles by Fujii, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichikawa, Y.
Right arrow Articles by Fujii, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Allergic Reactions to Oxaliplatin in a Single Institute in Japan

Yasushi Ichikawa1, Ayumu Goto1, Satoru Hirokawa1, Miyuki Kijima1, Takashi Ishikawa2, Takashi Chishima2, Hirokazu Suwa2, Harumi Yamamoto2, Shigeru Yamagishi2, Shunichi Osada2, Mitsuyoshi Ota2 and Shoichi Fujii2

1 Department of Clinical Oncology, Yokohama City University Graduate School of Medicine
2 Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan

For reprints and all correspondence: Yasushi Ichikawa, Department of Clinical Oncology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. E-mail: yasu0514{at}med.yokohama-cu.ac.jp

Received February 26, 2009; accepted May 24, 2009

Allergic reactions to oxaliplatin can be severe and are an important cause of discontinuation of treatment. A retrospective review was performed for 105 patients who received FOLFOX regimens between May 2005 and June 2007. Twenty-five cases (23.8%) of allergic reactions were identified, including 9 late onset reactions (8.6%) and 16 immediate reactions (15.2%). Severe allergy (Grades 3 and 4) occurred in seven patients (6.7%). Re-introduction of FOLFOX was attempted for seven immediate onset patients with a severity grade of 1 or 2, and three of these patients (42.9%) showed relapse of allergy. In ~10% of the patients, FOLFOX had to be discontinued due to allergy before the disease became refractory to the regimen. Our experience indicates that allergy to oxaliplatin may be a significant concern and that methods are required for suppression of this allergy.

Key Words: oxaliplatin • FOLFOX • allergy • hypoxemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.